AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16391401
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) for 3 months in IBM
Trial: 16391401
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) in SPS
Trial: 16391401
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) in DM
Trial: 12428313
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside infusion to maintain controlled hypotension with MAP around 60 mmHg
Trial: 9709937
Drug: Active/Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active/Placebo patch (AP group)
Trial: 9709937
Drug: Active/Active patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active/Active patch (AA group)
Trial: 9709937
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (PP group)
Trial: 2242951
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (10 capsules, three times daily)
Trial: 2242951
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil capsules (10 capsules, three times daily)
Trial: 29781315
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic treatment for Staphylococcus aureus (SA) colonization
Trial: 29781315
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic treatment
Trial: 30017459
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) with longitudinal formulation in the first 4 sessions
Trial: 27589523
Drug: Bapineuzumab 7
RxNorm normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 7 mg/month
Trial: 27589523
Drug: Bapineuzumab 2
RxNorm normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 2 mg/month
Trial: 27589523
Drug: Bapineuzumab 20
RxNorm normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 20 mg/month
Trial: 22086119
Drug: Intrasomatic injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAHEPATIC LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrasomatic injections of 4 mg/ml of dexamethasone phosphate followed by vertebroplasty
Trial: 15496046
Drug: Zinc (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (administered within 24 hours of onset of symptoms)
Trial: 15496046
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (administered as a nasal gel)
Trial: 8276366
Drug: Flumazenil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (2 mg, intravenous)
Trial: 8276366
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml solution, intravenous)
Trial: 2657048
Drug: salsalate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salsalate (3 g/day, adjusted for efficacy and tolerance)
Trial: 2657048
Drug: aspirin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin (3.6 g/day, adjusted for efficacy and tolerance)
Trial: 4613978
Drug: Dapsone, 100
RxNorm normalized name: Dapsone, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone, 100 mg daily for 14 consecutive days
Trial: 4613978
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for the remaining 56 days
Trial: 28554928
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (EA) with patient-controlled epidural administration of ropivacaine and sufentanil combined with standard care
Trial: 26715476
Drug: 0.05% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% chlorhexidine solution applied twice daily after usual oral hygiene care
Trial: 26715476
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no application after usual oral hygiene care
Trial: 21190403
Drug: Computer-assisted cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted cognitive-behavioral therapy (CBT)
Trial: 7266633
Drug: Various antibiotic
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various antibiotic regimens
Trial: 24451151
Drug: Daclatasvir 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 10 mg
Trial: 24451151
Drug: Daclatasvir 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 10 mg and 60 mg
Trial: 23112909
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of cholecalciferol (vitamin D(3)) for 3 weeks
Trial: 11371741
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (0.05 mg/kg per day)
Trial: 9564120
Drug: Long-acting opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting opioid medications
Trial: 8034823
Drug: Commitment-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commitment-based intervention (verbal and written commitments for adherence, tasks to increase investment in medication regimen)
Trial: 28297591
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement (oral 30 µg ethinyl estradiol or transdermal 100 µg 17‐β‐estradiol patch)
Trial: 17211116
Drug: Structured drug
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured drug education program
Trial: 12975729
Drug: Semitendinosus and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semitendinosus and gracilis tendon autografts (ST/G)
Trial: 3513567
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg folic acid per day
Trial: 27013640
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) plus metronidazole (MTZ) 400 mg TID and amoxicillin (AMX) 500 mg TID for 14 days
Trial: 27013640
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) plus metronidazole (MTZ) and amoxicillin (AMX)
Trial: 25012289
Drug: ISIS 329993
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 329993 (ISIS‐CRPR x) at 400 mg
Trial: 25012289
Drug: ISIS 329993
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 329993 (ISIS‐CRPR x) at 600 mg
Trial: 22449293
Drug: Rivaroxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily)
Trial: 22449293
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months
Trial: 18455592
Drug: Increased cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased cardiac troponin I levels (>0.92 ng/mL)
Trial: 18455592
Drug: Increased heart-type
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased heart-type fatty acid-binding protein levels (>6.8 ng/mL)
Trial: 15994267
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone (FP)
Trial: 15994267
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids (FP)
Trial: 1907840
Drug: Oral lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lithium carbonate (500 mg)
Trial: 6778757
Drug: intravenous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous fat emulsion (60% of the nonprotein energy) in addition to hypertonic glucose (51.5 +/- 5.0 kcal/kg/day)
Trial: 17986818
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received treatment as usual.
Trial: 27474496
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (videotapes of EOL and ED encounters)
Trial: 22909343
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg after each haemodialysis session
Trial: 22909343
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg daily
Trial: 15956789
Drug: Modified allergen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified allergen vaccine (maximum concentration 990 mug/ml, 100 times the maximum dose of native extract)
Trial: 15956789
Drug: Unmodified allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmodified allergen extract (maximum concentration 70 mug/ml, potency 10 HEP(L)/ml)
Trial: 9148259
Drug: Intact posterior
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact posterior capsule
Trial: 6206578
Drug: Radiation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation with bleomycin or vinblastine or a combination of both
Trial: 6206578
Drug: Larger radiation
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger radiation fraction and shorter treatment time schedule
Trial: 6206578
Drug: Radiation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation with chemotherapy
Trial: 28505227
Drug: Resveratrol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (500 mg/d) with exercise
Trial: 26868063
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (ISC)
Trial: 17241249
Drug: Rifaximin 200
RxNorm normalized name: rifAXIMin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 200 mg three times a day for 3 days
Trial: 15458569
Drug: Metadate CD
RxNorm normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metadate CD 20 mg
Trial: 15458569
Drug: Metadate CD
RxNorm normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metadate CD 40 mg
Trial: 15458569
Drug: Concerta 18
RxNorm normalized name: Concerta 18mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concerta 18 mg
Trial: 15458569
Drug: Concerta 36
RxNorm normalized name: Concerta 36mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concerta 36 mg
Trial: 10703815
Drug: Therapeutic monoclonal
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic monoclonal antibodies (mAb)
Trial: 3935343
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 20 mg
Trial: 29289554
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Testosterone + 50 mg Sildenafil
Trial: 29289554
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg Testosterone + 10 mg Buspirone
Trial: 23558873
Drug: Mifepristone 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 1200 mg every 12 hours with a high-fat meal
Trial: 15713143
Drug: C. pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. pneumoniae antibodies (IgG, IgA, IgM) measured using a solid‐phase enzyme immunoassay
Trial: 15713143
Drug: C. pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. pneumoniae antibodies (IgA, IgM)
Trial: 1477848
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg single oral dose)
Trial: 1477848
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg daily for 2 weeks)
Trial: 1477848
Drug: Propranolol (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (240 mg daily for 2 weeks)
Trial: 27787387
Drug: Saxagliptin add-on
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII)
Trial: 17945260
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (IVMP) pulses (1 g/day for 5 days with an oral prednisone taper, every 4 months for 3 years, then every 6 months for 2 years)
Trial: 17945260
Drug: IVMP only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVMP only for relapses (1 g/day for 5 days with an oral prednisone taper)
Trial: 15063963
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus Clomiphene Citrate (CC)
Trial: 9222709
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg daily and clarithromycin 500 mg b.i.d. (PC)
Trial: 9222709
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg daily, clarithromycin 500 mg b.i.d. plus amoxicillin 1 g b.i.d. (PCA)
Trial: 9222709
Drug: Bismuth subcitrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subcitrate 120 mg t.i.d., roxithromycin 150 mg b.i.d., metronidazole 250 mg b.i.d. plus ranitidin 300 mg (BRMR)
Trial: 8236398
Drug: Intramuscular quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular quinine (20 mg/kg followed by 10 mg/kg every 8 h)
Trial: 8236398
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine (20 mg/kg followed by 10 mg/kg every 8 h)
Trial: 3522030
Drug: Aluminum ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum ibuprofen 400 mg
Trial: 11777644
Drug: Sequential Boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Boost technique
Trial: 31368135
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine blood glucose control treatment)
Trial: 23061606
Drug: Intensive facial
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive facial exercises for 5 minutes after the first and third botulinum toxin-A treatment
Trial: 23061606
Drug: Rest in
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest in a seated position for 5 minutes after the second treatment (control group)
Trial: 23061606
Drug: Squeezing exercises
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Squeezing exercises after the second treatment (Group B)
Trial: 18520606
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg dose of norfloxacin (test formulation)
Trial: 18520606
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg dose of norfloxacin (reference formulation)
Trial: 12391117
Drug: Albuterol (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (inhaled bronchodilator)
Trial: 12391117
Drug: Salmeterol (3-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (3-week treatment)
Trial: 28707379
Drug: Angiolite drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiolite drug-eluting stent (DES)
Trial: 24647459
Drug: Moderate glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate glycemic index energy (MGI) bar (47.3 g CHO)
Trial: 15911704
Drug: Pyridostigmine 30
RxNorm normalized name: Pyridostigmine 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 30 mg orally
Trial: 12913835
Drug: High-titer (HT)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-titer (HT) Edmonston-Zagreb measles vaccine
Trial: 12913835
Drug: Standard-titer (ST)
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-titer (ST) measles vaccine
Trial: 8820174
Drug: Yohimbine HCl
RxNorm normalized name: yohimbine HCl
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine HCl (16 mg po) administered 30 min before clonidine (2 ug/kg infused over 10 min)
Trial: 8820174
Drug: Yohimbine HCl
RxNorm normalized name: yohimbine HCl
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine HCl (16 mg po) administered 30 min before apomorphine (0.5 mg sc)
Trial: 1445740
Drug: 12 week
RxNorm normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 week chemotherapy regimen
Trial: 1445740
Drug: 36 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 36 week chemotherapy regimen
Trial: 6538423
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus nimesulide 200 mg/d
Trial: 25302762
Drug: Schema-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema-therapy
Trial: 20496307
Drug: Kanamycin POS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kanamycin POS® eye ointment (5 times a day for 7 days)
Trial: 20496307
Drug: Placebo eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye ointment
Trial: 16098854
Drug: Paroxetine controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine controlled release (CR) 12.5 mg
Trial: 16098854
Drug: Paroxetine controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine controlled release (CR) 25 mg
Trial: 1221227
Drug: s.c. heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. heparin and dextran 40 (small doses)
Trial: 31377851
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (LNa, 15 mg kg‐1 day‐1)
Trial: 31377851
Drug: Usual diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual diet (UDiet, 46 (37-56) mg kg‐1 day‐1)
Trial: 31377851
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet (HNa, 100 mg kg‐1 day‐1)
Trial: 30235221
Drug: Daily self-report
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-report questionnaires
Trial: 30235221
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of PA monitors (Fitbit One™)
Trial: 25986296
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy combined with meditation
Trial: 15716214
Drug: Zaleplon 5
RxNorm normalized name: zaleplon 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon 5 and 10 mg nightly for 6 to 12 months
Trial: 12353407
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine (40 mL)
Trial: 12353407
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine (40 mL) plus clonidine (40 micrograms)
Trial: 268268
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (vincristine, 6-mercaptopurine, hydroxyurea, prednisone)
Trial: 7128841
Drug: Ortho‐Novum 1/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ortho‐Novum 1/50 tablets
Trial: 7128841
Drug: Ortho‐Novum 1/35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ortho‐Novum 1/35 tablets